Clinical pharmacology considerations in biologics development

Acta Pharmacologica Sinica

Volumn 33, Issue 11, 2012, Pages 1339-1347

  Zhao, Liang ^a   Ren, Tian Hua ^b   Wang, Diane D ^c  

^a OHIO STATE UNIVERSITY   (United States)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c PFIZER INC   (United States)

Author keywords

antibody; Biologics; clinical pharmacology; pharmacodynamics; pharmacokinetics

Indexed keywords

ABATACEPT; ANGIOPEPTIN; BASILIXIMAB; BIOLOGICAL PRODUCT; CILOSTAZOL; DAPTOMYCIN; DEGARELIX; DEHYDRODIDEMNIN B; EMFILERMIN; ENFUVIRTIDE; ETANERCEPT; HUMAN GROWTH HORMONE; INFLIXIMAB; METHOTREXATE; MONOCLONAL ANTIBODY; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; OCTREOTIDE; ONERCEPT; PEG INTRON A; PEGINESATIDE; PEGINTERFERON ALPHA2B; PRAMIPEXOLE; PREGABALIN; RANIBIZUMAB; RECOMBINANT BLOOD CLOTTING FACTOR 7A; RECOMBINANT ERYTHROPOIETIN; SILDENAFIL; TOCILIZUMAB; UNCLASSIFIED DRUG; UROFOLLITROPIN;

AREA UNDER THE CURVE; CLINICAL PHARMACOLOGY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG INTERACTION; DRUG METABOLISM; DRUG RECEPTOR BINDING; DRUG TARGETING; GENDER; GERIATRIC PATIENT; HUMAN; IMMUNOGENICITY; LIVER DYSFUNCTION; LIVER METABOLISM; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NONHUMAN; PHARMACODYNAMICS; QT PROLONGATION; RACE; RETROSPECTIVE STUDY; REVIEW; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CLINICAL TRIALS AS TOPIC; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; DRUG INTERACTIONS; GROWTH HORMONE; HUMANS; IMMUNOLOGIC FACTORS; PHARMACOLOGY, CLINICAL;

EID: 84868576131     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2012.51     Document Type: Review

References (39)

1. Roskos L, Ren S, Robbie G. Application of modeling and simulation in the development of protein drugs. In Kimko H and Peck C, editors. Clinical trial simulations AAPS advances in pharmaceutical sciences Series. New York: Springer Science+Business Media, LLC; 2011. p 361-96.
2. O'Driscoll C. Anatomy and physiology of the lymphatics. In Charman W, Stella V, editors. Lymphatic transport of drugs. Boca Raton (FL): CRC Press; 1992. p 1-36.
3. Lobo ED, Hansen RJ, Balthasar JP. Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 2004; 93:2645-68.
4. Wang W, Wang EQ, Balthasar JP. Monoclonal antibody pharma-cokinetics and pharmacodynamics. Clin Pharmacol Ther 2008; 84:548-58.
5. Antohe F, Radulescu L, Gafencu A, Ghetie V, M. Simionescu M. Expres sion of functionally active FcRn and the differentiated bidirectional transport of IgG in human placental endothelial cells. Hum Immunol 2001; 62:93-105.
6. Dickinson BL, Badizadegan K, Wu Z, Ahouse JC, Zhu X, Simister NE, et al. Bidirectional FcRn-dependent IgG transport in a polarized human intestinal epithelial cell line. J Clin Invest 1999; 104:903-11.
7. McCarthy KM, Yoong Y, Simister NE. Bidirectional transcytosis of IgG by the rat neonatal Fc receptor expressed in a rat kidney cell line: a system to study protein transport across epithelia. J Cell Sci 2000; 113:1277-85.
8. Bill A. Plasma protein dynamics: albumin and IgG capillary permeability, extravascular movement and regional blood flow in unanesthetized rabbits. Acta Physiol Scand 1977; 101:28-42.
9. Hedger MP, Hettiarachchi S. Measurement of immunoglobulin G levels in adult rat testicular interstitial fuid and serum. J Androl 1994; 15:583-90.
10. Juweid M, Strauss HW, Yaoita H, Rubin RH, Fischman AJ. Accumulation of immunoglobulin G at focal sites of infammation. Eur J Nucl Med 1992; 19:159-65.
11. Weinstein JN, Eger RR, Covell DG, Black CD, Mulshine J, Carrasquillo JA, et al. The pharmacology of monoclonal antibodies. Ann N Y Acad Sci 1987; 507:199-210.
12. Garg A, Balthasar JP. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice. J Pharmacokinet Pharmacodyn 2007; 34:687-709.
13. US Food and drug administration. Guidance for industry: Pharma-cokinetics in patients with impaired renal function-Study design, data analysis, and impact on dosing and labeling (Draft); 2010.
14. Dall'Acqua WF, Woods RM, Ward ES, Palaszynski SR, Patel NK, Bre-wah YA, et al. Increasing the affnity of a human IgG1 for the neonatal Fc receptor: biological consequences. J Immunol 2002; 169:5171-80.
15. Ghetie V, Popov S, Borvak J, Radu C, Matesoi D, Medesan C, et al. Increasing the serum persistence of an IgG fragment by random mutagenesis. Nat Biotechnol 1997; 15:637-40.
16. Murphy K, Travers P, Walport M. Janeway's Immunobiology. Garland Science; 2007.
17. De Vries MK, Brouwer E, van der Horst-Bruinsma IE, Spoorenberg A, van Denderen JC, Jamnitski A, et al. Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 2009; 68:1787-8.
18. Simponi (golimumab) injection, solution: US prescribing information. Horsham (PA): Janssen Biotech, Inc; 2011.
19. Schellekens H. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin Ther 2002; 24:1720-40.
20. BEXXAR (tositumomab) kit: US prescribing information. Research Triangle Park (NC): GlaxoSmithKline LLC; 2011.
21. Remicade (infiximab) injection: US prescribing information. Horsham (PA): Janssen Biotech, Inc; 2011.
22. Muller PY, Milton M, Lloyd P, Sims J, Brennan FR. The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies. Curr Opin Biotechnol 2009; 20:722-9.
23. Yu J, Karcher H, Feire AL, Lowe PJ. From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics. AAPS J 2011; 13:169-78.
24. Wang DD, Zhang S, Zhao H, Men AY, Parivar K. Fixed dosing versus body size-based dosing of monoclonal antibodies in adult clinical trials. J Clin Pharmacol 2009; 49:1012-24.
25. Zhang S, Shi R, Li C, Parivar K, Wang DD. Fixed dosing versus body size-based dosing of therapeutic peptides and proteins in adults. J Clin Pharmacol 2012; 52:18-28.
26. Mandema JW, Gibbs M, Boyd RA, Wada DR, Pfster M. Model-based meta-Analysis for comparative effcacy and safety: application in drug development and beyond. Clin Pharmacol Ther 2011; 90:766-9.
27. Mandema JW, Boyd RA, DiCarlo LA. Therapeutic index of anticoagulants for prevention of venous thromboembolism following orthopedic surgery: a dose-response meta-Analysis. Clin Pharmacol Ther 2011; 90:820-7.
28. Mandema JW, Salinger DH, Baumgartner SW, Gibbs MA. A dose-response meta-Analysis for quantifying relative effcacy of biologics in rheumatoid arthritis. Clin Pharmacol Ther 2011; 90:828-35.
29. Mandema JW, Cox E, Alderman J. Therapeutic beneft of eletriptan compared to sumatriptan for the acute relief of migraine pain-results of a model-based meta-Analysis that accounts for encapsulation. Cephalalgia 2005; 25:715-25.
30. Baxter LT, Zhu H, Mackensen DG, Butler WF, Jain RK. Biodistribution of monoclonal antibodies: scale-up from mouse to human using a physiologically based pharmacokinetic model. Cancer Res 1995; 55:4611-22.
31. Thygesen P, Macheras P, Van PA. Physiologically-based PK/PD modelling of therapeutic macromolecules. Pharm Res 2009; 26:2543-50.
32. Zhao L. New developments in using stochastic recipe for multi-compart ment model: inter-compartment traveling route, residence time, and exponential convolution expansion. Math Biosci Eng 2009; 6:663-82.
33. Zhao L, Li N, Yang H. A new stochastic approach to multi-compartment pharmacokinetic models: probability of traveling route and distri bu tion of residence time in linear and nonlinear systems. J Pharma-cokinet Pharmacodyn 2011; 38:83-104.
34. Hamuro LL, Kishnani NS. Metabolism of biologics: biotherapeutic proteins. Bioanalysis 2012; 4:189-95.
35. Huang SM, Zhao H, Lee JI, Reynolds K, Zhang L, Temple R, et al. Therapeutic protein-drug interactions and implications for drug develop ment. Clin Pharmacol Ther 2010; 87:497-503.
36. US Food and Drug Administration. Guidance for industry: General considerations for pediatric pharmacokinetic studies for drugs and biological products (Draft); 1998.
37. US Food and Drug Administration. Guidance for industry: E11 clinical investigation of medicinal products in the pediatric population; 2000.
38. US Food and Drug Administration. Guidance for Industry. Exposure-response relationships-study design, data analysis, and regulatory applications; 2003.
39. European Medicines Agency. CHMP Assessment Report for Ilaris; 2009.